​​​​​​​Medicines agencies around the world are in close dialogue with research scientists and pharmaceutical companies that are developing vaccines against covid-19. This also applies to the European Medicines Agency (EMA), to which Norway is affiliated. 

In March 2022, EMA set up the Emergency Task Force (ETF) which has taken over the activities of the COVID-19 EMA Pandemic Task Force (COVID-ETF) which was convened in March 2020 to address the COVID-19 pandemic. 

The responsibilities of the ETF includes providing scientific advice to developers for medicines that can address a public health emergency,  reviewing scientific data as well as providing scientific support to facilitate clinical trials in the EU for promising candidates.
For more information see EMAs webpage​

The approval process for covid-19 vaccines

The various vaccine technologies

Reported suspected adverse reactions of covid-19 vaccines

Oppdatert: 06.07.2022

Publisert: 14.07.2020

​Fant du det du lette etter?